Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InMode exhibited financial resilience in Q3 2023, with a modest increase in revenue and a significant rise in international sales. The stock price has recently declined but is now consolidating at lower levels, indicating a potential bottoming out. Despite operational challenges, InMode remains optimistic, projecting revenue between $500 million and $510 million for 2023.

InMode: Buying Opportunity At Oversold Market Levels

InMode Ltd. investors experienced a collapse in October 2023 as INMD fell to a three-year low. I assessed that buyers have returned in November, potentially helping INMD to form a pivotal long-term bottom. InMode's best-in-class profitability and attractive valuation support the constructive buying sentiments.

InMode: Why It's Now The Best Time To Buy

InMode, known for laser technology in cosmetic applications, faces a blend of market opportunities and financial challenges. INMD's innovative products like Morpheus8 and Evolve drive demand, but geopolitical and economic factors contribute to stock volatility. Financially strong with robust liquid assets and positive cash flow, but faces increased operational costs and margin pressures.

InMode's Dual-Edged Saga: Bright Prospects, Sharp Challenges

Recently, Zacks.com users have been paying close attention to InMode (INMD). This makes it worthwhile to examine what the stock has in store.

Investors Heavily Search InMode Ltd. (INMD): Here is What You Need to Know

InMode Ltd's share price fell by 25% in October due to the Israel-Hamas conflicts and lowered revenue guidance. The company operates in a niche market between plastic surgery and laser procedures, giving it a competitive advantage. InMode is well-positioned to benefit from the growing global medical aesthetic market and increasing demand for weight-loss drugs.

InMode: A Niche Medical Aesthetic Devices Player With Solid Financials

InMode (NASDAQ:INMD ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Miri Segal - Investor Relations Moshe Mizrahy - Chief Executive Officer and Chairman of Board of Directors Shakil Lakhani - President, North America Yair Malca - Chief Financial Officer Spero Theodorou - Chief Medical Officer Conference Call Participants Matt Miksic - Barclays Matthew Taylor - Jefferies Ryan Barocas - UBS Dane Reinhardt - Baird Mike Matson - Needham and Company Caitlin Cronin - Canaccord Genuity Operator Good day, and welcome to the InMode Third Quarter 2023 Earnings Results Conference Call. [Operator instructions] Please note today's event is being recorded.

InMode (INMD) Q3 2023 Earnings Call Transcript

YOKNEAM, Israel, Nov. 2, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2023.

InMode Reports Third Quarter 2023 Financial Results; Quarterly Revenue of $123.1M Represents 2% Year-Over-Year Growth

InMode (INMD) closed at $19.13 in the latest trading session, marking a -0.62% move from the prior day.

InMode (INMD) Registers a Bigger Fall Than the Market: Important Facts to Note

The business entered my High Quality and Bad Momentum Screener. War concerns have had limited impact on the company's sales and profitability, as most of its sales are from foreign markets. InMode revealed slashed EPS and revenue guidance for FY 2023 and Q3. The company has a strong balance sheet with a significant cash position, reflecting 34% of the current capitalization.

InMode: Overblown Reaction On Guidance, A Rare Valuation

InMode (INMD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why InMode Ltd. (INMD) is a Trending Stock

DexCom

DexCom is a big name in diabetes care, and investors may be overly bearish on the stock. InMode recently downgraded its guidance as rising interest rates impact its sales activity.

2 Healthcare Stocks Near Their 52-Week Lows That Could Double in Value

InMode shares experienced a significant drop of 20% in one trading day, but the decline is seen as excessively harsh. InMode's unique product line bridges the gap between surgical procedures and standard laser treatments, making it stand out in the market. Despite a downward revision of FY 2023 revenues, INMD stock remains undervalued and presents a buying opportunity.

The InMode Rollercoaster: Navigating The Revenue Adjustment

YOKNEAM, Israel , Oct. 13, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq:  INMD), a leading global provider of innovative medical technologies, announced that it filed a patent infringement complaint in the United States District Court for the Central District of California alleging that BTL Industries' UltraFemme 360 and EmFemme 360 non-invasive, radio-frequency based feminine rejuvenation products infringe U.S. Patent No.

InMode Files Patent Infringement Complaint Against BTL Industries, Inc. (d/b/a BTL Aesthetics)

Inmode Ltd shares sank 21% to $22.22 in late-morning trading on Thursday after the medical technologies provider announced that it now expects full year 2023 revenue to be in the range of $500 million to $510 million, down from previous estimates of between $530 million and $540 million.   Inmode cited factors including the current economic slowdown, slower purchase decisions due to lower aesthetic activity during the summer, and constraints in financing of medical equipment as a result of higher interest rates, tighter leasing approval standards, and bottlenecks in loan processing, all of which have impacted InMode platform sales activity globally.

Inmode stock drops on reduced revenue guidance

Conference call to be held on Thursday, Nov. 2, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 12, 2023 /PRNewswire/ -- InMode Ltd.

InMode Expects Third Quarter 2023 Revenue Between $122.8M-$123.0M, Lowering Full-Year 2023 Revenue Guidance to $500M-$510M vs. Original Estimates of $530M-$540M

YOKNEAM, Israel , Oct. 9, 2023 /PRNewswire/ --  InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, addressed today the status of the Company's activity in Israel.

InMode Affirms Safety of Management, Employees and Production Sites

NVIDIA

Exxon Mobil

After a miserable 2022, the stock market recovered in 2023 and surprised many investors. Artificial intelligence stocks grabbed the spotlight as investors dreamed of the possibilities.

Q4 Stock Predictions: 3 Stocks Ready to Roar Into 2024

InMode (INMD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Trending Stock InMode Ltd. (INMD) a Buy Now?

While we may have been bullish about INMD's eventual reversal to its historical valuations, it appears that our bullish investment thesis has been temporarily invalidated. This is despite the FQ2'23 double beats, raised FY2023 guidance, and optimistic forward commentary, with its "platforms being used more frequently, signifying increased brand recognition." Despite so, the INMD stock has retraced dramatically, way below the previous July 2023 levels to retest the March 2023 support levels.

InMode: Bullish Support Failed To Materialize

InMode's stock price has dropped significantly from its peak in 2021, despite consistently strong operational performance. In the meantime, the company's strong profitability has led to InMode featuring a substantial cash position relative to its market cap. Coupled with its shares appearing quite undervalued, InMode is positioned well to execute highly accretive buybacks, signaling upside potential.

InMode: Strong Net Cash Position Sets The Stage For Opportunistic Buybacks

Gevo

It's a well-known fact that the “big money” on Wall Street wants to draw retail investors' focus away from great stock deals. This is simply because if everyday investors are not buying the shares of such companies, the lack of competition enables large entities to quietly accumulate these forgotten stocks to buy at a much lower rate.

Betting Big: 3 Forgotten Stocks Primed for a Breakout

Is Most-Watched Stock InMode Ltd. (INMD) Worth Betting on Now?

InMode investors experienced significant volatility as INMD was hammered after its pre-earnings surge. As a result, it nearly gave up all its July gains. Investors are likely still concerned about the impact of high interest rates on medical capital equipment spending. Also, InMode's revenue growth could slow further through 2025. Despite that, dip buyers returned with conviction over the past two weeks, likely seeing attractive value in INMD following the steep plunge.

InMode: Be Greedy When Others Are Fearful

INMD's P/E and EV/EBITDA ratios have fallen sharply in the past 2-3 years despite its revenues and net income more than doubling in this period. The prospect of continued profitable growth and a history of beating analysts' estimates suggest that this undervaluation will not persist for long. INMD has insanely high gross margins and net income margins due to unique cost advantages that competitors like Cutera and Apyx lack.

InMode: Prolonged Valuation Slump Is A Buying Opportunity

Deere & Company

Perion Network

The stock market is filled with sleeper stocks that present tempting opportunities. Some investment ideas receive much of the spotlight.

News for Inmode Ltd Stock (INMD)